Want to see VANI full AI Analyst Report?
VANI Stock Chart & Stats
$1.28
-$0.02(-1.59%)
At close: 4:00 PM EST
$1.28
-$0.02(-1.59%)
Day’s Range― - ―
52-Week Range$0.92 - $1.92
Previous CloseN/A
Volume36.09K
Average Volume (3M)216.92K
Market Cap
$113.83M
Enterprise Value$79.94
Total Cash (Recent Filing)$19.75M
Total Debt (Recent Filing)$18.27M
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Aug 18, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding86,235,110
10 Day Avg. Volume237,036
30 Day Avg. Volume216,922
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)4.88
Price to Sales (P/S)0.00
P/FCF Ratio-3.01
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.83Price Target Upside199.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.33
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Program AdvancementRegulatory approval to start SLIM-1 Phase 1 is a durable development milestone: initiating first-in-human testing de-risks preclinical assumptions, creates an observable clinical timeline, enables meaningful safety/PK data and supports future dose‑ranging and partnership decisions over the next 6–18 months.
Strategic Validation From Novo NordiskEngagement by a leading GLP‑1 player provides external validation of Vivani's NanoPortal semaglutide implant approach. This strategic interest enhances credibility, increases partnership/licensing optionality, and could accelerate development or de-risk commercialization pathways if evaluations progress positively.
Recent Capital And RunwayA recent capital build and explicit runway through mid‑2027 provide stability to fund near‑term clinical milestones (SLIM‑1 dosing and Phase 1 data). This reduces immediate financing urgency, allowing management to focus on execution of trials and technical development over the next 6–12 months.
Bears Say
No Revenue & Heavy Cash BurnThe company remains pre‑revenue with substantial and persistent operating cash burn that mirrors accounting losses. Such a profile requires repeated external financing to sustain development and means long‑term viability hinges on successful clinical outcomes or partnerships rather than internal cash generation.
Rising LeverageMaterial increase in leverage versus prior years reduces financial flexibility and raises the probability of dilutive financing or restrictive covenants. With ongoing losses, higher debt levels amplify refinancing risk and constrain strategic options if development timelines slip.
Financing/transaction ConditionalityA key corporate transaction is explicitly conditional on new equity financing and approvals, exposing the company to execution and market‑timing risk. Dependence on contingent funding for restructuring or strategic deals increases dilution risk and could distract management from core clinical execution.
Vivani Medical News
VANI FAQ
What was Vivani Medical’s price range in the past 12 months?
Vivani Medical lowest stock price was $0.92 and its highest was $1.92 in the past 12 months.
What is Vivani Medical’s market cap?
Vivani Medical’s market cap is $113.83M.
When is Vivani Medical’s upcoming earnings report date?
Vivani Medical’s upcoming earnings report date is Aug 18, 2026 which is in 28 days.
How were Vivani Medical’s earnings last quarter?
Vivani Medical released its earnings results on May 13, 2026. The company reported -$0.08 earnings per share for the quarter, the consensus estimate of -$0.08 by $0.
Is Vivani Medical overvalued?
According to Wall Street analysts Vivani Medical’s price is currently Undervalued.
Does Vivani Medical pay dividends?
Vivani Medical does not currently pay dividends.
What is Vivani Medical’s EPS estimate?
Vivani Medical’s EPS estimate is -0.08.
How many shares outstanding does Vivani Medical have?
Vivani Medical has 86,235,110 shares outstanding.
What happened to Vivani Medical’s price movement after its last earnings report?
Vivani Medical reported an EPS of -$0.08 in its last earnings report, expectations of -$0.08. Following the earnings report the stock price went up 3.448%.
Which hedge fund is a major shareholder of Vivani Medical?
Currently, no hedge funds are holding shares in VANI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vivani Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.83 (199.48% Upside)
$3.83 (199.48% Upside)
Insider Transactions
Bought Shares
Worth $4.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.2%
Last 30 Days ▲ 16.3%
Last 30 Days ▲ 16.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.12%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
19.47%
Trailing 12-Months
Company Description
Vivani Medical
Vivani Medical, Inc. is a clinical-stage biopharmaceutical company that specializes in developing innovative implantable medical devices. The firm aims to address chronic diseases for which current treatments are insufficient or lacking. Its key initiatives include a portfolio of miniature drug implants, designed to ensure consistent and stable therapeutic drug delivery, as well as advanced implantable visual prostheses intended to provide meaningful artificial vision to blind individuals. Vivani Medical is headquartered in Emeryville, California.
VANI Stock 12 Month Forecast
Average Price Target
$3.83
▲(199.48% Upside)
Technical Analysis
Ownership Overview
48.71% Insiders
2.29% Mutual Funds
1.23% Other Institutional Investors
45.58% Public Companies and
Individual Investors